Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
3 Dividend Aristocrats Whose Yields Can Help Combat InflationWritten by Chris Markoch. Originally Published: 4/9/2026. 
Key Points
- Dividend Aristocrats including Amcor, Chevron, and AbbVie can provide reliable income streams that can help offset persistent inflation.
- Each of those three companies offers a yield above 3% combined with decades of consistent dividend growth, signaling strong financial stability.
- These stocks also provide exposure to defensive sectors like packaging, energy, and health care, which tend to perform well during periods of elevated inflation.
- Special Report: Elon’s “Hidden” Company
The calendar says it’s spring, but investors can be forgiven for feeling like it’s Groundhog Day: the economic issues affecting portfolios persist. Just after a ceasefire between the United States and Iran was announced—providing a market tailwind—investors are now getting fresh inflation readings that appear to be creeping higher. Both the Personal Consumption Expenditures (PCE) index and the Consumer Price Index (CPI) for March are due this week and are expected to show inflation edging up again. Sticky inflation remains a key concern.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Worse, the latest inflation numbers don’t yet fully reflect the impact of higher oil prices, which are typically inflationary. Whether that will be a short-term headwind or a longer-term problem remains to be seen. There are many layers to the inflation picture. Even if oil prices fall, a stronger economy could increase demand and push prices up. Interest rates matter too: the Federal Reserve has paused cuts, and a small but vocal contingent expects the next directional move in rates could be higher. One near-term reality is that inflation is unlikely to return to the Fed’s 2% target anytime soon. A sensible strategy today is to consider dividend stocks yielding more than 3%. Even if share prices don’t rise dramatically, growing dividend income can help preserve purchasing power. Rather than simply chasing yield, focus on companies with a track record of paying and reliably growing dividends. The following three Dividend Aristocrats—each with at least 25 consecutive years of dividend increases—fit that bill. Amcor Offers High Yield With Defensive DemandAmcor (NYSE: AMCR) is a global packaging company with market leadership across food and beverage, pharmaceutical, and personal care categories. Its products tend to be in steady demand, which can help during periods of economic uncertainty. That said, Amcor’s stock performance over the past year hasn’t excited investors—AMCR has been mostly flat over the last 12 months. Still, its dividend appears secure. The company has raised its payout for 27 consecutive years, a streak that includes dividends inherited from its 2019 Bemis acquisition. As of April 9, the yield was 6.3% with an annual payout of $2.60 per share. Amcor faces cost pressures from tariffs and higher oil prices. At roughly 27x earnings, AMCR is expensive relative to its historical valuation and the broader market. However, the dividend is well-supported, and analysts have a consensus one-year price target of $52, which would imply a gain of more than 20% in addition to the sizable yield. Chevron Combines Energy Exposure With Dividend StrengthEnergy stocks have been volatile since the late-February conflict with Iran began. Chevron (NYSE: CVX) has been a notable beneficiary—year to date, CVX is up nearly 30%. If oil stays elevated, Chevron owners will likely be rewarded. Even if oil prices retreat, Chevron remains a best-in-class integrated oil major. It’s increasing output not only in the United States but also more recently in Venezuela, and it has meaningful exposure to the growing liquefied natural gas market as well as strategic investments in renewable energy. The recent run-up has made CVX somewhat pricey in the short term. But investors should avoid conflating short-term price moves with the company’s long-term outlook. Over time, Chevron has been a good steward of capital: in 2025 it generated $20.2 billion in free cash flow and returned a record $27 billion to shareholders via dividends and buybacks. Chevron’s dividend yields about 3.6%, paying $7.12 per share annually, and the company has raised its payout for 38 consecutive years. AbbVie Delivers Reliable Growth and Income in Health CareHealth care isn’t the first sector investors think of for inflation protection, but demand for medicines tends to be durable. People don’t stop filling prescriptions when prices rise, which is why AbbVie (NYSE: ABBV) deserves attention. For fiscal 2025, AbbVie reported record revenue of $61.2 billion, with immunology sales up 14% led by Skyrizi and Rinvoq—products that have helped offset Humira’s patent expiration. That performance matters for the dividend story. While some feared Humira’s loss of exclusivity could pressure payouts, ABBV has continued to raise its dividend and now boasts an uninterrupted streak of 52 years. The yield is about 3.3%, equal to $6.92 per share annually. AbbVie is typically a stock to hold for income and long-term compounding rather than trade. Bottom line: In an inflationary environment, Dividend Aristocrats with yields above 3% and long records of rising payouts can provide income and relative resilience. Amcor, Chevron, and AbbVie each offer a different mix of yield, durability, and growth—investors should weigh valuation and company-specific risks before committing capital. |
Tiada ulasan:
Catat Ulasan